ClinicalTrials.gg
Not yet recruitingNCT07849387PACCTUpdated Sep 30, 2026

Sacrum Pressure Injury Prevention Study Using ALLEVYN◊ Complete Care in Adults at Risk of Developing Hospital-acquired Pressure Injuries in Critical Care Units

An interventional study of ALLEVYN◊ COMPLETE CARE Sacrum in Pressure Ulcers (Hospital-acquired Pressure Injuries), sponsored by Smith & Nephew, Inc.. Not yet recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Smith & Nephew, Inc. · Not applicable, Interventional, and Prevention

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Pressure Ulcer by Smith & Nephew, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Pressure Ulcer · Smith & Nephew, Inc..

Planned enrollment
Largest of 11
330 · median 25
Started
2026
the only one that year
No phase
6 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Pressure Ulcer by Smith & Nephew, Inc., this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 12th registered.

Pressure Ulcer

548 studies on the registry are indexed under Pressure Ulcer; 127 are open to participants now.

Browse Pressure Ulcer studies →

Open to participants now

1 of the 12 studies in Pressure Ulcer by Smith & Nephew, Inc. is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 61 Pressure Ulcer studies recruiting now, 45 (74%) set no upper age limit and 6 (10%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pressure Ulcer by Smith & Nephew, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to investigate the use of ALLEVYN◊ COMPLETE CARE Sacrum dressing for the prevention of hospital-acquired pressure injuries in adults. The main question it aims to answer is whether or not the dressing will prevent pressure injury prevention between application and Day 7. Participants will apply a dressing to the lower back/tailbone area as part of their regular care up to 14 days and participate in ongoing checkups by the study team.

Read the detailed description

Hospital-acquired pressure injuries (also known as pressure ulcers or bed sores) remain a common issue for patients confined to beds in hospitals. This study will see whether the use of a particular foam dressing (ALLEVYN◊ COMPLETE CARE Sacrum) in combination with standard pressure injury prevention protocols will reduce pressure injuries development compared to known rates of pressure injuries for adults receiving critical or intermediate hospital care. Participants will have the study dressing applied to the lower back/tailbone area, in addition to hospital standard methods used, to try to prevent pressure injuries. Study participation will last up to 14 days. Additional assessments will evaluate the severity and timing of any pressure injuries that occur, dressing utilization, clinician satisfaction with the dressing, dressing wear characteristics, health economic outcomes, and the relationship between pressure injury occurrence, skin tone and other risk factors.

03

Conditions studied

  • Pressure Ulcers (Hospital-acquired Pressure Injuries)

Browse trials for

Keywords

  • Pressure injury prevention
  • Hospital-acquired pressure injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject or legally authorized representative (LAR) provides written
  • Adults (≥18 years) at time of consent
  • Willing and able to complete all required study visits
  • Subjects admitted to Critical Care Units or Intermediate Care Units (may also be called step-down, progressive care, or high dependency units). Subjects may be identified in perioperative or emergency departments before moving to the appropriate unit.
  • Subject's Braden Scale score is ≤18 at time of screening
  • Subject is recruited within 18 hours of arrival to hospital (Emergency Department, perioperative area or Critical or Intermediate Care Units)
  • Subjects' is ≥3 days (as assessed by clinical judgment within 24 hours of consent)
  • Subjects expected Critical and/or Intermediate Care stay is ≥3 days (clinical judgment)

Exclusion criteria

Exclusion Criteria:

  • Subject has participated previously in this clinical trial
  • Subject is currently participating in or has participated in a clinical trial within thirty (30) calendar days of day 0 which could impact the scientific integrity of the study
  • Subject has a medical or physical condition that, in the opinion of the Investigator, would preclude safe participation in the study.
  • Subject has a known sensitivity/allergy to dressing and/or adhesive components (e.g., sensitivity to silicone)
  • Subject has a medical condition or orders that, in the opinion of the Investigator, prevent repositioning (e.g., hemodynamic instability or unstable spine) or positioning which would exclude the supine position (e.g., prone positioning) (clinical judgment)
  • Subjects with orders for, or expected to receive orders for, prone positioning (clinical judgment)
  • Known extended period, prior to enrolment, without documented repositioning in the opinion of the Investigator. e.g., Subject has had ≥6 hours of known pressure on the sacral area, subject found down, extended operating time etc.
  • Subject is currently receiving end-of-life care or comfort care only
  • Subject has existing sacral skin injury or has irregular skin features (e.g., tattoos, pre-existing scarring, evidence of prior healed pressure injury, unusual anatomy such as dimples or bony prominences) which in the opinion of the Investigator, will interfere with the study assessments.
  • Subject has uncontrolled/unmitigated urinary and/or fecal incontinence (e.g., controlled defined as incontinence reasonably managed through the use of a device such as indwelling catheter, fecal management system, external urinary catheter, etc.)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    ALLEVYN◊ COMPLETE CARE Sacrum

    ALLEVYN◊ COMPLETE CARE Sacrum as preventative measure for hospital-acquired pressure injuries

    Device: ALLEVYN◊ COMPLETE CARE Sacrum

Interventions

  • DeviceALLEVYN◊ COMPLETE CARE Sacrum

    ALLEVYN◊ COMPLETE CARE Sacrum foam dressing

06

What researchers measure

Primary outcomes

  1. Cumulative Incidence of Any Sacral Hospital-Acquired Pressure Injury Through Day 7

    The cumulative incidence of sacral hospital-acquired pressure injury (HAPI) is defined as the proportion of participants who developed any qualifying sacral HAPI up to and including Day 7 of study dressing application. A sacral skin assessment will be performed to determine whether any sacral HAPI has developed. "Yes" indicates detection of a sacral HAPI classified as Stage 1, Stage 2, Stage 3, Stage 4, unstageable pressure injury, or deep tissue pressure injury. "No" indicates the participant did not develop sacral HAPI by Day 7 or discontinued the study before Day 7 without developing sacral HAPI and was therefore considered event-free. Fewer pressure injuries indicate a better outcome.

    Time frame: Day 0 to Day 7

Secondary outcomes

  1. Cumulative Incidence of Sacral Hospital-Acquired Pressure Injury: Stage 2-4, Unstageable, and/or Deep Tissue Pressure Injury Through Day 7

    The cumulative incidence of sacral hospital-acquired pressure injury (HAPI) is defined as the proportion of participants who developed a stage 2-4, unstageable, or deep tissue HAPI up to and including Day 7 of study dressing application. A sacral skin assessment will be performed to determine whether a qualifying sacral HAPI developed. "Yes" indicates detection of a sacral HAPI classified as Stage 2, Stage 3, Stage 4, unstageable pressure injury, or deep tissue pressure injury. "No" indicates the participant did not develop a qualifying sacral HAPI by Day 7 or discontinued the study before Day 7 without developing a qualifying sacral HAPI and was therefore considered event-free. Fewer pressure injuries indicate a better outcome.

    Time frame: Day 0 to Day 7

  2. Cumulative Incidence of Each Sacral Hospital-Acquired Pressure Injury: Stage 1-4, Unstageable, and/or Deep Tissue Pressure Injury Through Day 7

    The cumulative incidence of sacral hospital-acquired pressure injury (HAPI) defined as the proportion of participants who developed stage 1-4, unstageable, or deep tissue HAPI up to and including Day 7 of study dressing application. A sacral skin assessment will be performed to determine whether a qualifying sacral HAPI developed. The sacral skin assessment will be categorized as one of the following: * Stage 1: Non-blanchable erythema of intact skin Intact skin * Stage 2: Partial-thickness skin loss with exposed dermis * Stage 3: Full-thickness skin loss in which adipose (fat) is visible * Stage 4: Full-thickness skin and tissue loss * Unstageable: Obscured full-thickness skin and tissue loss * Deep Tissue: Intact or non-intact skin with localized area of persistent non-blanchable deep red, maroon or purple discoloration

    Time frame: Day 0 to Day 7

  3. Number of Days to Clinical Diagnosis of Sacral Hospital-Acquired Pressure Injury (HAPI)

    For participants that develop a sacral hospital-acquired pressure injury (HAPI), the number of days from study dressing application on Day 0 to the clinical diagnosis of sacral HAPI will be summarized.

    Time frame: Day 0 to Day 14

  4. Dressing Utilization

    Dressing utilization will be summarized by the number of dressing changes throughout the treatment period, approximately 14 days.

    Time frame: Day 0 to Day 14

  5. Dressing Wear Time

    The duration of study dressing wear will be summarized as the total number of days the study dressing was worn during each 7-day period.

    Time frame: Day 0 to Day 14

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 23 months later.

Of 29 industry-sponsored interventional studies with no phase under Pressure Ulcer, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 27. This study's planned 23 months is above that.

Counting every sponsor, half of 210 studies reached it within 11 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Oct 24, 2028
CompletionEst.
Nov 7, 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849387
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Oct 24, 2028 (estimated)
Completion
Nov 7, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Jay Dobson
Contact
Jay.Dobson@smith-nephew.com
206-495-7058
Laura Everson
Contact
Laura.Everson@smith-nephew.com
Amanda Spitzer, MBA, RN
study chair · Smith & Nephew, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion